Transcenta Holding Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Transcenta Holding has been growing earnings at an average annual rate of 14.4%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 6.1% per year.
Información clave
14.4%
Tasa de crecimiento de los beneficios
50.5%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 11.0% |
| Tasa de crecimiento de los ingresos | -6.1% |
| Rentabilidad financiera | -39.8% |
| Margen neto | -1,606.2% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastos
Cómo gana y gasta dinero Transcenta Holding. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 22 | -359 | 96 | 277 |
| 31 Mar 24 | 38 | -411 | 108 | 330 |
| 31 Dec 23 | 54 | -463 | 119 | 382 |
| 30 Sep 23 | 85 | -451 | 115 | 385 |
| 30 Jun 23 | 116 | -440 | 112 | 387 |
| 31 Mar 23 | 109 | -424 | 112 | 369 |
| 31 Dec 22 | 102 | -407 | 112 | 350 |
| 30 Sep 22 | 74 | -666 | 137 | 349 |
| 30 Jun 22 | 45 | -925 | 161 | 348 |
| 31 Mar 22 | 53 | -1,748 | 153 | 383 |
| 31 Dec 21 | 50 | -1,716 | 147 | 344 |
| 30 Sep 21 | 65 | -1,457 | 153 | 317 |
| 30 Jun 21 | 79 | -1,199 | 160 | 290 |
| 31 Mar 21 | 82 | -364 | 166 | 223 |
| 31 Dec 20 | 81 | -317 | 158 | 200 |
| 31 Dec 19 | 44 | -395 | 123 | 215 |
Ingresos de calidad: 6628 is currently unprofitable.
Margen de beneficios creciente: 6628 is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 6628 is unprofitable, but has reduced losses over the past 5 years at a rate of 14.4% per year.
Acelerando crecimiento: Unable to compare 6628's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 6628 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Rentabilidad financiera
Alta ROE: 6628 has a negative Return on Equity (-39.76%), as it is currently unprofitable.